Vitae Pharmaceuticals Earns $14 Million Milestone Payment from Boehringer Ingelheim in Alzheimer's Collaboration - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Vitae Pharmaceuticals Earns $14 Million Milestone Payment from Boehringer Ingelheim in Alzheimer's Collaboration

  • SPONSORED BY SOUTHEAST HEALTHMore>>

  • BJC changes charity care standards

    BJC changes charity care standards

    Sunday, April 20 2014 1:01 PM EDT2014-04-20 17:01:10 GMT
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
  • Clock ticking for states to adopt health exchanges

    Clock ticking for states to adopt health exchanges

    Friday, April 18 2014 2:39 PM EDT2014-04-18 18:39:20 GMT
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time...
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time is...
  • Blood test aims to predict breast cancer's return

    Blood test aims to predict breast cancer's return

    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.
    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Vitae Pharmaceuticals

- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program

FORT WASHINGTON, Pa., Feb. 20, 2014 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, best-in-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI's initiation of a Phase 1 clinical trial in the companies' beta-secretase (BACE) inhibitor program for Alzheimer's disease.

"This achievement offers new promise for those suffering from Alzheimer's disease - patients who are urgently in need of new treatment options," said Jeff Hatfield, CEO of Vitae.  "Our strong working relationship with Boehringer has produced great science, and the opportunity to deliver a best-in-class compound to patients."  The collaboration aims to discover and develop BACE inhibitors to slow or halt the formation of amyloid-beta plaques that accumulate in the brains of Alzheimer's patients and are widely associated with the disease.  Within 18 months of Vitae initiating full-scale research efforts on BACE, Vitae partnered with BI, generating $42 million in upfront and research funding and the opportunity to earn more than $200 million in pre-commercial payments in addition to sales milestones and royalties.

"This marks Vitae's third discovery program to advance into the clinic in the last four years," said Hatfield, "exemplifying the remarkable productivity and efficiency of our drug discovery platform." 

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage, privately-held biopharmaceutical company discovering and developing a portfolio of novel, small molecule, best-in-class compounds that address important disease areas, with clinical programs in chronic kidney disease, diabetes and Alzheimer's disease, and preclinical programs in autoimmune disorders, acute coronary syndrome and immuno-oncology.

Vitae strives to be best in the world at structure-based drug discovery, combining an advanced, proprietary platform with the insights of a small team of world class scientists, to rapidly discover and advance first- and/or best-in-class compounds for high value targets.  The success of Vitae's discovery approach and business model has allowed the company to grow in a highly capital efficient and self-sustaining manner.  Vitae's last venture round dates back ten years, to 2004.

For additional information, please visit the company's website at www.vitaepharma.com.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.